Shares of Yduqs surged 15.1% to BRL 8.56 on August 24, recovering from a punishing earnings-driven selloff, after the Brazilian education giant confirmed it is in preliminary merger discussions with Afya, the country's dominant medical-school operator. Afya confirmed the discussions are "at an early stage" , and no binding agreement or commitment has been entered into by either side.
Afya's German parent, Bertelsmann, is driving the talks — representatives already met in São Paulo, with a follow-up session planned for September.
A Deal Would Create a Brazilian Education Powerhouse — On Paper
Afya is Brazil's leading medical-education platform, backed by one of the world's largest media conglomerates, while Yduqs ranks among the country's biggest higher-education groups, operating brands like Estácio and enrolling hundreds of thousands of students.
A combination could dramatically widen the merged entity's reach across multiple education segments. The complementary fit is obvious: Afya's high-margin medical schools — which posted a 41.8% adjusted EBITDA margin in Q2 2026 — bolted onto Yduqs' mass-market scale.
Yduqs Arrives at the Table Wounded
Yduqs reported adjusted net income of just R$14 million in Q2 2026, down 54.2%, and swung to a small net loss on a reported basis.
Its distance-learning base fell 6.9% after Brazil barred remote intake in key fields.
The stock had declined over 40% in the prior six months , which means Bertelsmann may see an opportunity to buy Yduqs' sprawling campus network at a steep discount. At current prices, Yduqs trades at roughly 0.4x trailing sales — bargain-bin territory for a company generating R$756 million in operating cash flow in the first half alone.
Afya's Shareholders May Be Harder to Convince
Afya grew Q2 revenue 5.7% to R$972 million and produced R$406.5 million in EBITDA.
Management touted an implied 24% annual equity return at constant valuation. Taking on Yduqs' 177% debt-to-equity ratio and its struggling distance-learning unit would dilute those metrics. The strategic logic — pairing Afya's premium medical margins with Yduqs' scale — only works if regulators and minority shareholders on both sides sign off.
September Talks Will Be the Real Test
Conversations remain at an early stage, with no binding proposal, no valuation framework, and no agreed ownership structure. Today's pop prices in hope, not certainty. Yduqs is targeting net debt-to-EBITDA of 1.0x by end-2027 , a goal that a merger could accelerate — or derail. Investors should watch the September meeting for signs of a formal offer; until then, the 15% jump is a bet on a handshake that may never become a contract.